Crystalys Therapeutics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Crystalys Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Crystalys Therapeutics: 3 sponsored US clinical trials, 3 recruiting.
Crystalys Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tophaceous Gout, with 1 trials.
Upper-quartile sponsor footprint
Crystalys Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
NCT07535034
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
Where Crystalys Therapeutics enrollment is open (later-stage tilt)
3 recruiting of 3 indexed (100% open).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Tophaceous Gout (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Crystalys Therapeutics: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Crystalys Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Crystalys Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Crystalys Therapeutics or any single study.
- 3 of Crystalys Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Tophaceous Gout is the condition Crystalys Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tophaceous Gout trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Crystalys Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.